Clinical Trials Logo

Clinical Trial Summary

Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer


Clinical Trial Description

Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study.

Primary objectives: Safety Immunological efficacy, expressed as number of patients who show enhancement of the proportion of circulating immune effectors specific for a selected panel of Colon-Rectal Cancer (CRC)-associated antigens.

Secondary objectives: Clinical outcome of the patients (OS, RFS, TTR). To evaluate the predictive role of the development of a positive DTH test after at least three vaccine administrations.

To evaluate the persistence of an antitumor immune response after the completion of the vaccination program.

To evaluate the prognostic or predictive role of the enhancement of a specific immune response.

To evaluate a panel of inflammatory cytokines involved in antitumor immune response.

To evaluate the predictive role of immune cells in tumour microenvironment. To evaluate the predictive role of tumour antigen expression.

This is a two-stage, phase 2 clinical trial designed according to Simon minimax design. A 40% immune response rate would preclude further studies, while a 70% immune response rate would indicate that further studies would be warranted. Given α and β error of 0.1, the first stage will require enrolment of 7 patients. If at least 3 patients show an immune response and toxicity is acceptable, the study will proceed to the second stage and additional 12 patients will be enrolled.

The vaccine will be considered immunologically active if at least 11 patients are immunological responders. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02919644
Study type Interventional
Source Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Contact Oriana Nanni, PhD
Phone +390543739266
Email oriana.nanni@irst.emr.it
Status Recruiting
Phase Phase 2
Start date December 2, 2016
Completion date April 2024

See also
  Status Clinical Trial Phase
Completed NCT01704703 - Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques Phase 2
Terminated NCT02960282 - Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
Completed NCT01998152 - Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT) N/A
Not yet recruiting NCT06287723 - French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
Completed NCT03005002 - Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver Phase 1
Completed NCT03095781 - Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Phase 1
Terminated NCT03111823 - Exercise Program During Chemotherapy in Metastatic Colorectal Cancer N/A
Active, not recruiting NCT04267575 - Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites N/A
Recruiting NCT03368963 - TAS102 in Combination With NAL-IRI in Advanced GI Cancers Phase 1/Phase 2
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Active, not recruiting NCT01271582 - Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients Phase 4
Active, not recruiting NCT03800602 - Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer Phase 2
Recruiting NCT05631574 - Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Phase 1
Completed NCT03112668 - Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners N/A
Terminated NCT01550510 - Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA Phase 1/Phase 2
Completed NCT03373188 - VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer Phase 1
Terminated NCT04044430 - Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Phase 1
Completed NCT05025748 - Ask Questions (ASQ):Implementation of a Communication Intervention N/A
Completed NCT01722903 - Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer N/A
Completed NCT02809716 - High Definition Single Cell Analysis in Colorectal Cancer